Future focus: Our 2020 vision

Sponsored by Cambrex

February 11, 2020

Our vision 

As we enter a new decade, the next 12 months represent another opportunity for investment and growth. Having expanded operations beyond small molecule API development and manufacturing into the drug product segment, we are investing in our sites, capabilities and people to maintain our leading position as the small molecule company.

Our commitment

We have doubled the cGMP liquid-filling capacity at our Mirabel, Québec, Canada facility. Strategic expansion at our Edinburgh, Scotland facility, including an increase in headcount and investment in new equipment in Europe, will enable us to serve more customers in the solid-state screening market. The new 6,500-square-foot facility at our site in Karlskoga, Sweden, which incorporates labs for process and analytical development, is also now complete.

This will help us with our strategy of providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers. These are exciting times. As always, we will do our best at Cambrex to serve you, our customers, by being the experts you enjoy working with.

Shawn Cavanagh
President & Chief Operating Officer, Cambrex

Enjoy our latest Cambrex expert insights by downloading the latest eBooks:

Download Part 1 of the Cambrex 2020 eBook

Download Part 2 of the Cambrex 2020 eBook